Lower baseline prostate-specific antigen is associated with a greater overall survival benefit from sipuleucel-T in the Immunotherapy for Prostate Adenocarcinoma Treatment (IMPACT) trial (Q44599299)
Jump to navigation
Jump to search
scientific article published on 9 April 2013
| Language | Label | Description | Also known as |
|---|---|---|---|
| English | Lower baseline prostate-specific antigen is associated with a greater overall survival benefit from sipuleucel-T in the Immunotherapy for Prostate Adenocarcinoma Treatment (IMPACT) trial |
scientific article published on 9 April 2013 |
Statements
1 reference
Lower baseline prostate-specific antigen is associated with a greater overall survival benefit from sipuleucel-T in the Immunotherapy for Prostate Adenocarcinoma Treatment (IMPACT) trial (English)
1 reference
1 reference
Paul F Schellhammer
1 reference
Gerald Chodak
1 reference
James B Whitmore
1 reference
Robert Sims
1 reference
Mark W Frohlich
1 reference
9 April 2013
1 reference
1 reference
1 reference
1 reference
1 reference
1 reference
1 reference
1 reference
1 reference
1 reference
1 reference
1 reference
1 reference
1 reference
1 reference
1 reference
1 reference
1 reference
1 reference
Identifiers
1 reference